| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | 0.0093 | 0.9 |
| mRNA | BRD-A02303741 | CTRPv2 | pan-cancer | AAC | 0.0079 | 0.9 |
| mRNA | AZD7762 | GDSC1000 | pan-cancer | AAC | 0.0089 | 0.9 |
| mRNA | AM-580 | CTRPv2 | pan-cancer | AAC | -0.0074 | 0.9 |
| mRNA | vorapaxar | CTRPv2 | pan-cancer | AAC | -0.0075 | 0.9 |
| mRNA | BRD-K33514849 | CTRPv2 | pan-cancer | AAC | -0.023 | 0.9 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.011 | 0.9 |
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | -0.0084 | 0.9 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.0073 | 0.9 |
| mRNA | shikonin | GDSC1000 | pan-cancer | AAC | 0.0082 | 0.9 |